X
PTC shares soar after SMA drug data impresses market
https://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/
spinal muscular atrophy
Biogen courts controversy with $750k-a-year rare disease drug
Biogen’s SMA treatment approved – but price is $125,000 per dose
Biogen names new CEO
Chief commercial officer Michel Vounatsos promoted to top job.
Biogen to file spinal muscular atrophy drug
Phase 3 success triggers $75m payment to Ionis.